• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

Do Women at Increased Risk for Down Syndrome Following Standard Screening Prefer NIPT or Invasive Testing?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • While NIPS (NIPT) may have perceived benefit of no risk of fetal loss, it is not diagnostic
  • Invasive testing is diagnostic and current risk of loss is substantially less than previously reported (see ‘Related ObG topics below)
  • Guidelines recommend women be offered invasive testing following an initial ‘high risk’ standard screen for Down syndrome (trisomy 21)
  • Cheng et al. (BJOG, 2017) sought to determine whether women who were screen positive (high or intermediate risk) for Down syndrome following standard screening and appropriate counseling would opt for NIPS or invasive testing

METHODS:

  • Prospective cohort study
  • Inclusion: Women with high risk (term risk ≥ 1:250) or intermediate risk (term risk between 1:251-1:1200) standard screening results for Down syndrome
  • Exclusion: Multiple or  non-viable  pregnancies; fetuses  with  structural  abnormalities  or hydrops  at  the  time  of  screening; already  had a  private  self-financed  NIPS
  • Women at high risk were given the following options
    • Diagnostic invasive test/chromosomal microarray
    • NIPS to detect trisomies 13, 18 and 21
    • Decline further testing
  • Women at high risk received standardized counseling, including need to confirm positive NIPS results; procedure miscarriage risk was described as 0.1-0.2%
  • Women with intermediate risk (IR) between 1:251 -1:1200 were offered NIPT as a secondary screening test
  • Testing options were free and wait time for results were equivalent
  • The primary outcome was NIPS uptake rate

RESULTS:

  • 99.1% of 347 of women with high risk results opted for follow-up testing
  • 216 women (62.2%) chose NIPS
  • Only factors correlated with women opting for microarray were
    • Down syndrome risk between 1:2 to 1:9 compared to those with a risk between 1:10 to 1:250
    • Nuchal translucency ≥3.5mm
  • 507 (82.6%) of 614 women with IR risk chose NIPS
    • NIPS detected one additional case of trisomy 18 and Trisomy 21, but also missed one case of Trisomy 18 and Trisomy 21

CONCLUSION:

  • Even when cost is not an issue, 60% of women at high risk for Down syndrome still chose a noninvasive, non-diagnostic, less comprehensive option

Learn More – Primary Sources:

Women’s Preference For Non-Invasive Prenatal DNA Testing (NIPT) Versus Chromosomal Microarray After Screening For Down Syndrome: A Prospective Study.

image_pdfFavoriteLoadingFavorite

< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Down Syndrome / Trisomy 21: Clinical Findings and Prenatal Considerations
Fetal loss after amnio or CVS – what is the risk ?
Should Amniocentesis or Chorionic Villus Sampling Be Offered to All Pregnant Women?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site